Lazolvan

Lazolvan: a mucolytic agent for the treatment of bronchopulmonary diseases

Lazolvan is a mucolytic agent that is widely used to treat bronchopulmonary diseases. It contains ambroxol as an active substance, which helps improve mucus discharge and ease breathing.

Lazolvan is produced by several companies in different countries, including Boehringer Ingelheim in Poland, Italy and Germany, German Remedies Ltd in India and Eczacibasi in Turkey. It is available in various dosage forms including tablets, injections, inhalations, syrups and others.

The drug is actively used for the treatment of bronchitis, pneumonia, bronchial asthma with difficulty in sputum discharge, bronchiectasis and respiratory distress syndrome in premature infants and newborns.

However, like any medicine, Lazolvan has its contraindications and side effects. It is not recommended for hypersensitivity, gastric and duodenal ulcers, pregnancy (first trimester) and breastfeeding. Side effects may include weakness, headache, gastralgia, nausea, vomiting, diarrhea, exanthema and others.

It is also important to remember that Lazolvan can interact with other drugs, increasing the penetration of amoxicillin, cefuroxime, erythromycin and doxycycline into the bronchial secretions. The injection solution is pharmaceutically incompatible (in one syringe) with solutions of drugs whose pH exceeds 6.3.

Some special instructions for the use of Lazolvan also include the need to take into account that 5 ml of syrup contains sorbitol and saccharin in an amount corresponding to 0.18 XE (may be important for patients with diabetes). In addition, Lazolvan should not be combined with other antitussives that make it difficult to remove sputum.

In general, Lazolvan is an effective mucolytic agent for the treatment of bronchopulmonary diseases. However, its use should be accompanied by consultation with a doctor and compliance with the instructions for use.